Your fact-checks will appear here
The ongoing research into the use of ivermectin to treat cancer, including case reports and early trials.
Standard single-dose antiparasitic regimens of oral ivermectin produce plasma levels in the low nanomolar range, whereas multi‑day oncology schedules being tested raise both total exposure and peak le...
Preclinical work identifies strongest anticancer signals for ivermectin in breast cancer, hematologic malignancies (notably leukemia), hepatocellular carcinoma, and several drug-resistant solid tumor ...
Preclinical mouse studies of ivermectin report effective antitumor activity across a wide dose range—commonly 0.5–10 mg/kg and in some reviews up to 40 mg/kg—with many experiments using ~3–10 mg/kg to...
Clinicians must identify or exclude high Loa loa microfilaremia before giving ivermectin in endemic areas because serious adverse events—including encephalopathy and death—are tightly linked to high c...